Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Quality Assurance: SOP for Risk Mitigation Strategies in QA Activities – V 2.0

Posted on By

Quality Assurance: SOP for Risk Mitigation Strategies in QA Activities – V 2.0

Standard Operating Procedure for Risk Mitigation Strategies in Quality Assurance Activities


Department Quality Assurance
SOP No. SOP/QA/185/2025
Supersedes SOP/QA/185/2022
Page No. Page 1 of 14
Issue Date 24/06/2025
Effective Date 26/06/2025
Review Date 24/06/2026

1. Purpose

To establish a comprehensive and proactive approach for risk identification, evaluation, mitigation, and control in Quality Assurance (QA) activities. This ensures adherence to GMP and ICH Q9 principles and minimizes the impact of quality risks in

sterile injectable manufacturing.

2. Scope

This SOP applies to all QA processes including batch record review, deviation management, audit findings, product release, vendor qualifications, and change control management within sterile injectable manufacturing units.

3. Responsibilities

  • QA Officer: Assists in identifying potential risks and documenting them.
  • QA Manager: Leads risk evaluation meetings and assigns mitigation actions.
  • Functional Departments: Participate in risk evaluation and implement assigned mitigation measures.
  • QA Head: Reviews and approves all risk mitigation plans and ensures effectiveness checks.
See also  Sterile Injectable Manufacturing: SOP for Formulation Development of Intraosseous Injections - V 2.0

4. Accountability

The Head of Quality Assurance is accountable for ensuring that all QA risks are identified and appropriately mitigated as per the risk assessment and control measures outlined in this SOP.

5. Procedure

5.1 Risk Identification

  1. Identify potential QA risks during:
    • Deviation and change control reviews
    • Batch record evaluations
    • Audit observations
    • Out-of-trend (OOT) or OOS incidents
    • QA walkthroughs or inspections
  2. Document identified risks in the Risk Register (Annexure-1).

5.2 Risk Evaluation

  1. Use a qualitative or semi-quantitative method based on:
    • Severity (impact of risk)
    • Occurrence (likelihood)
    • Detection (ability to detect before impact)
  2. Calculate Risk Priority Number (RPN) = Severity × Occurrence × Detection.
  3. Classify RPNs as:
    • Low (RPN ≤ 40)
    • Medium (41 ≤ RPN ≤ 80)
    • High (RPN > 80)

5.3 Risk Mitigation Strategy

  1. Based on the risk rating, determine appropriate mitigation actions:
    • Low Risk – Monitor and document
    • Medium Risk – Develop CAPA plan and assign timelines
    • High Risk – Immediate action and escalation to QA Head
  2. Document mitigation actions in the Risk Assessment Form (Annexure-2).
See also  Sterile Injectable Manufacturing: SOP for Conducting Quality Audits in Injectable Manufacturing - V 2.0

5.4 Risk Control Implementation

  1. Assign responsibility for each mitigation action to relevant personnel.
  2. QA shall track progress using the Mitigation Tracker (Annexure-3).
  3. Mitigation effectiveness is evaluated through:
    • Reduction in similar deviations or non-conformances
    • Successful audit outcomes
    • Review of batch release trends

5.5 Risk Communication and Review

  1. Communicate risks and mitigation status during monthly QA review meetings.
  2. Perform a quarterly risk assessment trend analysis and summarize for the QA dashboard.
  3. Update the Risk Register with closure dates and effectiveness outcomes.

6. Abbreviations

  • SOP: Standard Operating Procedure
  • QA: Quality Assurance
  • RPN: Risk Priority Number
  • CAPA: Corrective and Preventive Action
  • OOT: Out of Trend
  • OOS: Out of Specification

7. Documents

  1. Risk Register – Annexure-1
  2. Risk Assessment Form – Annexure-2
  3. Mitigation Tracker – Annexure-3
See also  Sterile Injectable Manufacturing: SOP for Handling Out-of-Specification Results during In-Process Testing - V 2.0

8. References

  • ICH Q9 – Quality Risk Management
  • WHO TRS No. 981 Annex 2 – Risk Management Principles
  • 21 CFR Part 211 – Subpart F: Production and Process Controls

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation QA Executive QA Manager Head QA
Department Quality Assurance Quality Assurance Quality Assurance

11. Annexures

Annexure-1: Risk Register

Risk ID Identified Risk RPN Status
RISK-QA-0024 Delayed batch record review 75 Open

Annexure-2: Risk Assessment Form

Risk ID RISK-QA-0024
Severity 5
Occurrence 5
Detection 3
RPN 75
Mitigation Plan Review training, establish dual-review process
Owner Sunita Reddy

Annexure-3: Mitigation Tracker

Action Item Owner Due Date Status
Establish dual-review SOP Rajesh Kumar 30/06/2025 In Progress

Revision History:

Revision Date Revision No. Details Reason Approved By
01/05/2022 1.0 Initial release New SOP Head QA
24/06/2025 2.0 Added RPN method and mitigation tracker Annual update Head QA
Injectables V 2.0 Tags:Aseptic processing SOP, Aseptic technique in sterile manufacturing, Cleanroom SOP for injectables, SOP for ampoule sealing, SOP for autoclave sterilization, SOP for container closure integrity testing, SOP for environmental monitoring in aseptic area, SOP for gowning in cleanroom, SOP for in-process checks in sterile manufacturing, SOP for injectable formulation, SOP for lyophilizer operation, SOP for sterile filtration, SOP for sterilization validation, SOP for vial filling, SOP for visual inspection of injectables, Sterile area cleaning SOP, Sterile filling line SOP, Sterile injectable quality control SOP, Sterile injection SOP, Sterile manufacturing procedure

Post navigation

Previous Post: Gel Manufacturing: SOP for Cleaning Verification of Gel Manufacturing Equipment – V 2.0
Next Post: SOP Training During Equipment/Process Validation

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version